Back to top
more

Ironwood Pharmaceuticals (IRWD)

(Delayed Data from NSDQ)

$4.13 USD

4.13
1,384,226

-0.16 (-3.73%)

Updated Aug 24, 2026 04:00 PM ET

After-Market: $4.12 -0.01 (-0.24%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.80%
2Buy18.13%
3Hold10.19%
4Sell5.73%
5Strong Sell3.17%
S&P50011.53%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value A Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 39% (102 out of 246)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Ironwood Initiates Phase III Studies on Reflux Candidate

by Zacks Equity Research

Ironwood (IRWD) initiates two phase III studies on its gastrointestinal candidate, IW-3718, to evaluate it in persistent gastroesophageal reflux disease.

    Zacks Equity Research

    Ironwood Pharmaceuticals (IRWD) Down 10.3% Since Earnings Report: Can It Rebound?

    by Zacks Equity Research

    Ironwood Pharmaceuticals (IRWD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

      Zacks Equity Research

      Ironwood (IRWD) Incurs Loss in Q1, Announces Restructuring

      by Zacks Equity Research

      Ironwood Pharmaceuticals (IRWD) misses estimates on both counts in the first quarter. The company will be separated into two entities for better management.

        Zacks Equity Research

        Ironwood (IRWD) Beats Estimates in Q4 Earnings, Stock Up

        by Zacks Equity Research

        Ironwood Pharmaceuticals (IRWD) beats estimates on both counts in the fourth quarter. Demand for Linzess continues to rise.

          Zacks Equity Research

          Ironwood Succeeds in Diabetic Hypertension Phase II Study

          by Zacks Equity Research

          Ironwood Pharmaceuticals' (IRWD) pipeline candidate, IW-1973, reduces blood pressure and improves metabolic parameters in type II diabetes with hypertension patients in a phase IIa study.

            Zacks Equity Research

            Ironwood (IRWD) Beats Estimates in Q3 Earnings, Stock Up

            by Zacks Equity Research

            Ironwood Pharmaceuticals (IRWD) beats estimates on both counts in the third quarter. Demand for Linzess rises.

              Zacks Equity Research

              Ardelyx IBS-C Candidate Succeeds in Pivotal Study, Stock Up

              by Zacks Equity Research

              Ardelyx's (ARDX) tenapanor reduces abdominal pain and improves bowel movements in a phase III study evaluating the drug in irritable bowel syndrome with constipation.

                Zacks Equity Research

                Why Is Ironwood (IRWD) Down 4.1% Since the Last Earnings Report?

                by Zacks Equity Research

                Ironwood (IRWD) reported earnings about a month ago. What's next for the stock? We take a look at earnings estimates for some clues.

                  Zacks Equity Research

                  Ironwood Pharma's Combination Gout Drug Gets FDA Approval

                  by Zacks Equity Research

                  Ironwood Pharmaceuticals, Inc. (IRWD) announced that the FDA has approved Duzallo for the treatment of hyperuricemia in patients with uncontrolled gout.

                    Zacks Equity Research

                    Ironwood (IRWD) Q2 Loss Widens, Revenues Miss, Stock Up

                    by Zacks Equity Research

                    Ironwood Pharmaceuticals' (IRWD) second-quarter results were dismal, missing sales and earnings estimates.